Clinical Trials
497 trialsGDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Dana-Farber Cancer Institute
ORCHID
Fudan University
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Fox Chase Cancer Center
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
University of Washington
SAFIR-ABC10
UNICANCER
Trastuzumab in Treating Women With Metastatic Breast Cancer
Centre Antoine Lacassagne
TAPUR
American Society of Clinical Oncology
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
A Study of Surgery and Radiotherapy in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
SPECTACLE
Fudan University
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Alliance for Clinical Trials in Oncology
I-SPY
QuantumLeap Healthcare Collaborative
ASCENdANT
Duke University
NeoTHERa
University of Kansas Medical Center
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
UC HER
National Taiwan University Hospital
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
PHERGAIN-2
MedSIR
OPTIMAL-BC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Dana-Farber Cancer Institute
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
EUREKA
Rutgers, The State University of New Jersey
DTP
The Methodist Hospital Research Institute
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Peking University Cancer Hospital & Institute
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Hebei Medical University Fourth Hospital
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Fudan University
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
MINUTE
Isala
TRAP-BTC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
ctDNA in HER2+ EBC Neoadjuvant Treatment
Shanghai Jiao Tong University School of Medicine
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
University of Nebraska
CHANCES
Institut Paoli-Calmettes
BRIDGET
Duke University
TSARINE
Centre Oscar Lambret
IPATHER
SOLTI Breast Cancer Research Group
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
University of California, Irvine
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
H. Lee Moffitt Cancer Center and Research Institute
Opti-HER2
National Medical Research Radiological Centre of the Ministry of Health of Russia
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
Dana-Farber Cancer Institute
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
City of Hope Medical Center